Edith Cowan University

Research Online
Research outputs 2022 to 2026
1-1-2022

Activity of newest generation β-lactam/β-lactamase
-lactam/ -lactamase inhibitor
combination therapies against multidrug resistant Pseudomonas
aeruginosa
Robbie R. Haines
Papanin Putsathit
Edith Cowan University, p.putsathit@ecu.edu.au

Katherine A. Hammer
Anna S. Tai

Follow this and additional works at: https://ro.ecu.edu.au/ecuworks2022-2026
Part of the Chemicals and Drugs Commons
10.1038/s41598-022-21101-x
Haines, R. R., Putsathit, P., Hammer, K. A., & Tai, A. S. (2022). Activity of newest generation β-lactam/β-lactamase
inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa. Scientific reports, 12, Article
16814. https://doi.org/10.1038/s41598-022-21101-x
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworks2022-2026/1368

www.nature.com/scientificreports

OPEN

Activity of newest generation
β‑lactam/β‑lactamase inhibitor
combination therapies
against multidrug resistant
Pseudomonas aeruginosa
Robbie R. Haines1*, Papanin Putsathit2, Katherine A. Hammer1 & Anna S. Tai3,4,5
Multidrug resistant (MDR) P. aeruginosa accounts for 35% of all P. aeruginosa isolated from respiratory
samples of patients with cystic fibrosis (CF). The usefulness of β-lactam antibiotics for treating
CF, such as carbapenems and later generation cephalosporins, is limited by the development of
antibacterial resistance. A proven treatment approach is the combination of a β-lactam antibiotic
with a β-lactamase inhibitor. New β-lactam/β-lactamase inhibitor combinations are available, but
data are lacking regarding the susceptibility of MDR CF-associated P. aeruginosa (CFPA) to these
new combination therapies. In this study we determined MIC values for three new combinations;
imipenem-relebactam (I-R), ceftazidime-avibactam (CZA), and ceftolozane-tazobactam (C/T) against
MDR CFPA (n = 20). The MIC90 of I-R, CZA, and C/T was 64/4, 32/4, and 16/8 (all µg/mL), respectively.
The susceptibility of isolates to imipenem was not significantly improved with the addition of
relebactam (p = 0.68). However, susceptibility to ceftazidime was significantly improved with the
addition of avibactam (p < 0.01), and the susceptibility to C/T was improved compared to piperacillin/
tazobactam (p < 0.05) These data provide in vitro evidence that I-R may not be any more effective than
imipenem monotherapy against MDR CFPA. The pattern of susceptibility observed for CZA and C/T in
the current study was similar to data previously reported for non-CF-associated MDR P. aeruginosa.
Cystic fibrosis (CF) is a genetic disease affecting the osmotic control of airway mucus. The resulting mucus is
thick and tenacious, which impairs the mucociliary elevator, obstructs the flow of air, and impedes immune effectors from reaching the airways efficiently1. As a result of these disease features, bacterial infection is common in
the CF patient p
 opulation1. Pseudomonas aeruginosa is responsible for the majority of bacterial lung infections
in the adult CF population; in 2019 77.6% of Australian CF patients older than 25 years had P. aeruginosa present
in their respiratory t ract2. Colonisation and infection with CF-associated P. aeruginosa (CFPA) are significant
events in the clinical course of the CF, and are associated with increased morbidity and m
 ortality3.
P. aeruginosa has intrinsic resistance to many antimicrobials and also has a propensity to both develop and
acquire antimicrobial resistance (AMR) genes through mutation and horizontal gene transfer, r espectively4. One
method by which resistance may develop to β-lactam antibiotics in particular is by horizontal gene transfer of
genes encoding β-lactamases5. In the twentieth century, a major clinical breakthrough was the discovery of compounds that bind to β-lactamases and inhibit their activity. These compounds (namely tazobactam, sulbactam,
and clavulanic acid) decrease the effective rate of hydrolysis of β-lactam antibiotics by some β-lactamases, thereby
renewing antimicrobial action against bacteria that relied on those enzymes for r esistance6,7.
Unfortunately, the range of β-lactamases that these original three β-lactamase inhibitors can act upon is
limited, causing an evolutionary pressure for these enzymes to mutate and become inhibitor r esistant7. As
with all AMR, there is an artificial selection pressure created leading to the proliferation of inhibitor-resistant
β-lactamases7. Generally speaking, tazobactam/sulbactam/clavulanic acid are active against class A and class D
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CLSI breakpoints
Test agent

MIC50

MIC90

Range

S

I

I-R

32/4

64/4

< 0.5/4–128/4

≤ 2/4

4/4

R
≥ 8/4

CZA

8/4

32/4

< 1/4–> 512/4

≤ 8/4

–

≥ 16/4

C/T

2/1

16/8

< 0.5/0.25–64/32

≤ 4/4

8/4

≥ 16/4

Table 1.  MIC values for CFPA isolates (n = 20). All values are in µg/mL.

serine β-lactamases, but not class B metallo-β-lactamases or class C serine β-lactamases7. Recent innovations
have led to the development and licencing of new β-lactamase inhibitors that have activity against all serine
β-lactamase (classes A, C, and D)8. The three new non-β-lactam β-lactamase inhibitors currently available are
vaborbactam (with meropenem), avibactam (with ceftazidime), and relebactam (with imipenem [IPM] and cilastatin). Also, another recent innovation has led to the synthesis of a new cephalosporin with anti-pseudomonal
activity, ceftolozane, which is available in combination with tazobactam.
Prior epidemiological and in vitro studies suggest that ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T) are effective therapies against β-lactam resistant P. aeruginosa (61.8–70.2%, and 72.5–78.7% of isolates
susceptible, respectively)9,10. Meropenem/vaborbactam is active against narrower range of MDR P. aeruginosa
isolates (59.0%)11. Imipenem/relebactam (I-R) is a more recent therapy and therefore the data are limited, however, some data suggest that the addition of relebactam may not be sufficient to lower the MIC of IPM below a
clinically useful level in P. aeruginosa that produce β-lactamases12.
The high prevalence of multidrug resistant (MDR) CFPA is of particular concern and accounts for 35% of
all CFPA in the Australian adult CF patient population13. New β-lactam/β-lactamase inhibitor combinations
are available, but the in vitro efficacy of these new combinations is not well established against CFPA isolates.
CFPA isolates have a different distribution of genotypes compared to P. aeruginosa isolates not originating
from CF14. Due to these genetic differences and the unique physiological conditions present in the CF airway,
atypical phenotypes such as mucoid variants and small colony variants have emerged15–17. These macroscopic
phenotypic changes are evidence of other more subtle changes in the phenome, some of which may include
acquisition/expression of β-lactamases. Due to the phenotypic divergence of CFPA from non-CFPA, the efficacy
of antimicrobials against this group must be verified. In this study we determined the MIC of I-R, CZA, and C/T
against MDR CFPA isolates.

Results

MICs of I-R, CZA, and C/T for CFPA isolates (n = 20) are shown in Table 1. Of particular note are the MIC50
values for CZA and C/T which fall below the Clinical and Laboratory Standards Institute (CLSI) breakpoints
that indicate susceptibility to those agents. Twenty percent (n = 3/15) of IPM resistant isolates were I-R susceptible, 68.8% (n = 11/16) of ceftazidime (CAZ) resistant isolates were CZA susceptible, and 68.8% (n = 11/16) of
piperacillin/tazobactam (TZP) resistant isolates were C/T susceptible. Complete results for each isolate are shown
in Table 2, and full sensitivities at the screening stage are showing in Supplementary Table S1. The addition of
relebactam to IPM did not significantly change resistance to IPM alone (p = 0.6831), however the addition of
avibactam to CAZ significantly altered resistance (p = 0.0094). The change from TZP to C/T had a significant
effect on resistance phenotype (p = 0.0265). Some strains showed some level of phenotypic variance in that they
would be sensitive to the single agent, but become phenotypically resistant when the inhibitor was added (e.g.:
CFPA 04).

Discussion

In this study we have demonstrated the in vitro antimicrobial efficacy of three new antipseudomonal treatments,
I-R, CZA and C/T, against CFPA isolates.
Only a modest proportion of IPM resistant isolates were I-R susceptible. This suggests that relatively few
isolates had class A or class C β-lactamase-mediated IPM resistance. This is an expected result, as the majority
of IPM resistance is mediated by changes in membrane permeability associated with inactivation of the efflux
pump oprD, which is unaffected by β-lactamase inhibitors, including r elebactam18. I-R may be useful in infections
caused by the subset of CFPA isolates that have IPM resistance mediated by class A or class C β-lactamases only.
Relebactam does not have class B metallo-β-lactamase or class D serine β-lactamase activity, and therefore I-R
should not be considered when these enzymes are either suspected or confirmed to be a resistance mechanism
in the target i solate12.
Our results are discordant with I-R susceptibility data for non-CFPA isolates, which indicate that approximately 80% of MDR isolates are susceptible to I-R19. β-lactamase-mediated resistance is more common in nonCFPA and non-β-lactamase mechanisms such as oprD inactivation are responsible for the some IPM resistance
in MDR C
 FPA20.
The majority of CAZ resistant isolates were CZA susceptible, which is consistent with the literature for MDR
non-CFPA isolates9,10. The relatively high proportion of CAZ resistant isolates that were also CZA susceptible
suggests that the majority of CAZ resistance is mediated primarily by serine β-lactamases which have interactions
with avibactam. Avibactam is known to interact strongly with class A, class C, and some class D β-lactamases21.
Piperacillin is used as a comparator to ceftolozane given that they both share tazobactam as a combination
agent, and also have similar uses in the clinic in the context of P. aeruginosa. Predictably, the majority of TZP
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Isolate

Possible MLST STs (strain)a

IPMb

I-Rc

CAZb

CZAc

TZPb

C/Tc

CFPA 01

649 (AUST-01)

R

R

R

S

R

S

CFPA 02

649 (AUST-01)

R

R

R

S

R

S

CFPA 03

775 (AUST-02)

R

R

S

R

S

R

CFPA 04

775 (AUST-02)

S

R

R

S

R

S

CFPA 05

775 (AUST-02)

S

S

R

S

R

S

CFPA 06

242 (AUST-03), 996

S

R

R

R

R

R

CFPA 07

242 (AUST-03), 996

R

R

R

R

R

S

CFPA 08

787, 788 (AUST-04)

R

S

R

S

S

S

CFPA 09

4, 801 (AUST-06), 1292

R

R

R

R

R

R

CFPA 10

4, 801 (AUST-06), 1292

R

R

R

R

R

R

CFPA 11

262 (AUST-07), 774, 1165

R

R

S

S

S

R

CFPA 12

262 (AUST-07), 774, 1165

S

R

S

S

S

S

CFPA 13

882 (AUST-11), 1151, 1233

R

S

S

S

R

S

CFPA 14

882 (AUST-11), 1151, 1233

S

S

R

S

R

S

CFPA 15

905 (AUST-16), 1039

R

R

R

S

R

S

CFPA 16

905 (AUST-16), 1039

R

R

R

R

R

R

CFPA 17

12 (AUST-33)

R

R

R

S

R

S

CFPA 18

254 (AUST-38), 1041 (AUST-38)

R

R

R

S

R

S

CFPA 19

217 (Manchester), 1134

R

S

R

S

R

S

CFPA 20

217 (Manchester), 1134

R

R

R

S

R

R

ATCC® 27,853

115

S

S

S

S

S

S

PAO1

549

S

S

S

S

S

S

Total susceptibled (%) (n = 20)

25

25

20

70

20

65

Table 2.  Genotypes and AMR phenotypes of isolates used in this study. IPM imipenem, I-R imipenem/
relebactam, CAZ ceftazidime, CZA ceftazidime/avibactam, TZP piperacillin/tazobactam, C/T ceftolozane/
tazobactam. a Genotypes (MLST STs) associated with the iPLEX20SNP profile. Named strains associated with
genotypes indicated in bold. b Susceptibility determined by disk diffusion assay. c Susceptibility determined by
broth microdilution assay. d Excludes reference strains P. aeruginosa ATCC® 27,853 and P. aeruginosa PAO1.

resistant isolates were C/T susceptible, demonstrating that the newest generation cephalosporin, ceftolozane,
has a wider spectrum of activity compared to the ureidopenicillin piperacillin.
The proportions of MDR CFPA isolates in this study that were susceptible to CZA, and C/T are consistent with
values reported in the literature for MDR non-CFPA9,10,12. This suggests that for CZA and C/T there is not yet a
divergent resistance phenotype in CFPA, and that research to-date involving MDR P. aeruginosa and these agents
can be broadly applied to MDR CFPA. Data from both the current and previous studies should be interpreted
with some measure of caution as none of the conventionally used antibiotic susceptibility testing methods (disk
diffusion assay, agar dilution assay, broth microdilution assay) account for the dynamic in vivo environment.
One such consideration is the presence of biofilm. P. aeruginosa is a biofilm-forming organism, and the mature
biofilm of P. aeruginosa confers tolerance to antimicrobials by virtue of limiting drug diffusion22. This is an
important determinant of AMR and must always be considered in the treatment of P. aeruginosa infections22,23.
Having determined whether an organism is susceptible to an antimicrobial agent, the effective delivery of
that antimicrobial must also be considered. Due to the altered whole body systems physiology present in CF
patients, antimicrobial pharmacokinetics/pharmacodynamics are a ffected24. A pertinent example is the enhanced
renal (and total) clearance of β-lactam antibiotics in the CF patient p
 opulation24. Due to this niche pharmacokinetic difference, subinhibitory concentrations may develop quicker during intermittent dosing regimens in
the CF patient population. Therapeutic drug monitoring and/or continuous dosing can be used to address this
problem24,25.
Whilst this study provides important in vitro data supporting the clinical use of new combinations, it is
important that the potential for MDR CFPA to develop resistance to these combinations also be evaluated. The
CFPA isolates that were used in this study were naïve to I-R, CZA, and C/T, and there has been no opportunity
allowed for our isolates to develop mutations conferring resistance on any meaningful timescale. However, it is
clear that there was short-term variations in resistance phenotype. This is exemplified by resistance to a combination therapy, but susceptibility to the monotherapy. This may be an on-going limitation when performing in vitro
susceptibility testing on hypermutative bacteria such as CFPA. Additional studies examining the propensity for
organisms to develop and propagate resistance to these antimicrobial agents is needed at both the laboratory and
population health scale, especially considering resistance mechanisms against each of the β-lactam/β-lactamase
inhibitor combinations in this study have been identified and reported in the l iterature26–28.
Our results indicate a high proportion of CFPA isolates that are resistant to IPM are also resistant to I-R,
however CAZ resistant isolates may be susceptible to CZA, and TZP resistant isolates may be susceptible to C/T.
Where possible, antibiotic susceptibility testing should always be used to identify appropriate antimicrobial
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agents, and good prescribing practices should continue to reflect this important component of antimicrobial
stewardship.

Materials and methods

Experimental isolates. Sputum samples were collected at the Western Australian Adult Cystic Fibrosis
Centre between January 2017 and May 2018. All samples were cultured for P. aeruginosa. Collection of sputum
samples was approved by the Sir Charles Gairdner Hospital Human Research Ethics Committee (SCGH HREC
RGS 0000001815) and in accordance with institutional policies and procedures; informed consent was obtained
from all patients. Any P. aeruginosa strains isolated subsequently underwent antimicrobial susceptibility testing
via the disk diffusion assay against meropenem, IPM, TZP, cefepime, CAZ, aztreonam, colistin, tobramycin,
gentamicin, amikacin, ciprofloxacin, and levofloxacin. The disk diffusion assay was performed and interpreted
according the CLSI guidelines29,30. Based on these results, isolates were categorised as non-MDR or MDR using
consensus criteria31. The genotype of each isolate was determined using iPLEX20SNP, a validated method using
MassARRAY MALDI-TOF MS which is described elsewhere32. All isolates included in this study were obtained
from samples provided by unique patients and were obtained on separate clinic visits. For these reasons, isolates with identical iPLEX20SNP profiles were considered unlikely to be clonal. P. aeruginosa ATCC® 27853 was
included as a quality control organism and P. aeruginosa PAO1 was included as a comparator.
Determination of MICs. A broth microdilution assay was used to determine the MICs of I-R, CZA, and
C/T. The procedure followed is described in the CLSI standard, and the results were interpreted using the CLSI
published breakpoints, shown in Table 130,33. MICs were determined visually and verified by measuring the
OD600 of each well of the microplate before and after incubation. A ≥ 90% reduction in OD600 compared to the
positive growth control was considered to be inhibitory and was the method used to determine MIC values. The
spectrophotometric method corresponded well with the results obtained visually.
Antimicrobial agents. CAZ, IPM, relebactam, and avibactam (item numbers HY-B0593, HY-B1369,
HY-16752, and H-14879A) were purchased from MedChemExpress. Ceftolozane was not available as a single
agent, and therefore the clinical formulation of C/T (ARTG 229608) was used. Since this formulation contained
ceftolozane in a fixed concentration of 2:1 with tazobactam (1 g/0.5 g), this represents a variance form the CLSI
protocol which uses a tazobactam concentration of 4 µg/mL in all microplate test w
 ells30,34.
Statistical analyses. All MIC values were obtained in biological triplicates for each strain and the modal

value was reported as the MIC value in this study. For the purposes of analysis, isolates that had MICs falling in
the intermediate breakpoint range were reported as resistant. McNemar’s test was performed to test for statistical
significance between the resistance of IPM and I-R, CAZ and CZA, TZP and C/T. P values less than 0.05 were
considered significant. McNemar’s tests were performed using the free browser tool QuickCalcs provided by
GraphPad Software LLC (https://www.graphpad.com/quickcalcs/).

Data availability

All data generated is contained within the tables published.
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